Medigen Vaccine Biologics Corp.
Medigen Vaccines Biologics Corp. is dedicated to developing and mass-producing vaccines and biopharmaceuticals. With PIC/S GMP certification, the company specializes in cell culture technology and has the capacity for large-scale vaccine production. It focuses on global and regional infectious diseases, including COVID-19, enteroviruses, and dengue fever, aiming to become a leader in the vaccine and biopharmaceutical industry. The company emphasizes quality, innovation, and social responsibility, contributing to global health and sustainable development.
Industries
Medigen Vaccine Biologics Corp.
Products
Enterovirus A71 vaccine (candidate)
Parenteral vaccine candidate targeting Enterovirus A71 developed with clinical data including infant cohorts; intended for prevention of EV-A71-associated disease.
Quadrivalent seasonal influenza vaccine (QIV)
Licensed quadrivalent seasonal influenza vaccine formulation obtained via technology licensing for local distribution.
Tetravalent dengue vaccine (technology-transferred candidate)
Development of a tetravalent dengue vaccine candidate derived from externally licensed live-attenuated vaccine technology.
RSV monoclonal antibody biosimilar development
Collaborative development program for RSV-targeting monoclonal antibody biosimilars conducted within an international consortium framework.
Protein-subunit COVID-19 vaccine (recombinant S-2P) candidate
Protein subunit vaccine candidate based on a recombinant stabilized spike (S-2P) antigen developed via technology transfer for COVID-19 prevention.
Enterovirus A71 vaccine (candidate)
Parenteral vaccine candidate targeting Enterovirus A71 developed with clinical data including infant cohorts; intended for prevention of EV-A71-associated disease.
Quadrivalent seasonal influenza vaccine (QIV)
Licensed quadrivalent seasonal influenza vaccine formulation obtained via technology licensing for local distribution.
Tetravalent dengue vaccine (technology-transferred candidate)
Development of a tetravalent dengue vaccine candidate derived from externally licensed live-attenuated vaccine technology.
RSV monoclonal antibody biosimilar development
Collaborative development program for RSV-targeting monoclonal antibody biosimilars conducted within an international consortium framework.
Protein-subunit COVID-19 vaccine (recombinant S-2P) candidate
Protein subunit vaccine candidate based on a recombinant stabilized spike (S-2P) antigen developed via technology transfer for COVID-19 prevention.
Services
GMP vaccine manufacturing and contract production
Commercial-scale production of vaccine bulk and finished doses at a PIC/S GMP-certified facility to support supply and distribution.
Technology transfer and partnership development
Structured licensing, technology transfer and alliance support with international research institutes and public-health organizations for vaccine and biologic development.
Clinical development and trial execution support
Design and operational execution of Phase I–III clinical trials including randomized, double-blind and immunobridging studies across multiple centers.
Analytical testing and immunogenicity assays
Neutralization and serology testing to measure vaccine-induced antibody responses and variant neutralization.
GMP vaccine manufacturing and contract production
Commercial-scale production of vaccine bulk and finished doses at a PIC/S GMP-certified facility to support supply and distribution.
Technology transfer and partnership development
Structured licensing, technology transfer and alliance support with international research institutes and public-health organizations for vaccine and biologic development.
Clinical development and trial execution support
Design and operational execution of Phase I–III clinical trials including randomized, double-blind and immunobridging studies across multiple centers.
Analytical testing and immunogenicity assays
Neutralization and serology testing to measure vaccine-induced antibody responses and variant neutralization.
Expertise Areas
- Vaccine research and development
- Clinical trial management and immunobridging
- Bioprocess development and commercial scale-up
- Regulatory compliance and quality assurance (GMP, CE marking)
Key Technologies
- Cell-culture vaccine manufacturing
- PIC/S GMP manufacturing
- Recombinant protein subunit vaccines (stabilized spike antigens)
- Virus-like particle (VLP) platforms